logo
That Cup of Coffee and Glass of Wine Are Staining Your Teeth. Here's How to Keep Your Smile Bright Without Giving Up Your Favorite Drinks

That Cup of Coffee and Glass of Wine Are Staining Your Teeth. Here's How to Keep Your Smile Bright Without Giving Up Your Favorite Drinks

CNET4 days ago
If you're anything like me, morning coffee is non-negotiable. It's the one thing I look forward to every morning and gets me out of bed. The same can be said about wine. Some can't seem to forgo that nightcap, whether it's a crisp white on a patio or a bold red on a date night.
As much as these drinks off us joy, they can also secretly sabotage our smiles. Over time, you might start noticing that your once bright teeth are looking a little dull. So that begs the question: How do you enjoy coffee and wine without turning your teeth a few shades darker? I asked Dr. Anjali Rajpal, board-certified dentist at Beverly Hills Dental Arts, to break it down and offer dentist-approved ways to prevent staining without sacrificing your favorite drinks.
Why do coffee and wine stain your teeth?
The short answer is a combination of chromogens (a substance that can be colorless but can be converted into a colored compound, often through a chemical reaction), tannins and acidity.
"Coffee and red wine stain teeth because they contain dark pigments called chromogens that stick to enamel. Tannins in these drinks help the pigments bind more strongly to the teeth. Their acidity also weakens enamel, making it easier for stains to set in," Rajpal told CNET. She explains that darker roasts and concentrated coffee like espresso tend to stain teeth more than lighter brews. Likewise, red wine stains more than white, especially darker, tannin-rich varieties like cabernet sauvignon and malbec. "The longer these drinks stay in contact with your teeth, the more likely they are to cause staining," Rajpal said.
Read more: The 8 Best Coffee Subscriptions of 2025, Tested by Coffee Lovers
Does some coffee or wine stain your teeth more than others?
It turns out that, yes, certain types of coffee and wine can stain your teeth more. "Darker roasts and concentrated coffee like espresso tend to stain teeth more than lighter brews. Red wine stains more than white, especially darker, tannin-rich varieties like cabernet sauvignon and malbec," Rajpal explains. She also mentions that the longer these drinks stay in contact with your teeth, the more likely they are to cause staining.
The type of coffee and wine isn't the only thing you should consider when trying to keep your teeth white. The temperature of a drink can influence how much it can stain your teeth. Hot beverages are more likely to cause stains than iced ones. "Heat can slightly expand enamel, making it more porous and allowing pigments to penetrate more easily," Rajpal said. "While iced drinks may have less impact due to quicker consumption and lower enamel exposure, the type and frequency of the drink matter more overall."
Boy_Anupong/Getty Images
Tips to keep your teeth white without sacrificing your favorite drinks, according to a dentist
Protecting your teeth from stains doesn't mean you have to give up your morning cup of Joe. Follow these dentist-approved tips to keep your pearly whites healthy and bright:
Sip your drink through a straw
Straws help the liquid bypass your front teeth, minimizing the contact that leads to visible staining. Rajpal recommends using a straw for iced drinks and rinsing your mouth with water afterward" to reduce staining from coffee or wine.
Drink your coffee or wine in one sitting
One of the worst things you can do is sip your coffee or wine slowly for hours. "Sipping slowly throughout the day constantly exposes your enamel to staining compounds and gives your teeth less time to recover, making stains more likely to build up over time," Rajpal says. Try to enjoy your drink over a 15- to 30-minute period, then rinse with water after.
Rinse, don't brush, right after
I know this one seems counterintuitive, but brushing your teeth right after you have coffee or wine can actually do more harm. "Avoid brushing immediately after drinking, as acids can soften enamel and make it more vulnerable," Rajpal recommends. "Wait at least 30 minutes before brushing to protect softened enamel, and give a break between snacking or eating to boost natural cleansing by saliva."
Pair your drink with enamel-friendly foods
Certain foods can help neutralize acid and reduce the length of time pigments stay on teeth. Rajpal recommends crunchy foods like apples, carrots and celery, which gently scrub teeth and boost saliva, which helps wash away pigments. Cheese and leafy greens create a protective layer on enamel, while strawberries contain natural acids that can mildly brighten teeth.
kiboka/Getty Images
Maintain teeth-whitening habits
It's best to wait at least 30 minutes before brushing to protect softened enamel. Timing also matters -- give your teeth a break between snacking or eating to boost natural cleansing by saliva. Rajpal also recommends products like remineralizing toothpaste and minimal intervention paste (a topical tooth cream that protects teeth and can improve overall oral hygiene).
How to whiten teeth stained by coffee or wine
If your teeth are already showing signs of staining, there are things you can do to whiten your teeth at home or at the dentist's office.
Get a professional cleaning
Before trying whitening products, Rajpal recommends scheduling a professional cleaning to remove surface stains and plaque buildup. For deeper stains, you can consider whitening treatments like in-office whitening or custom take-home trays. Maintaining results requires good oral hygiene and limiting staining habits.
Try gentle at-home whitening products
One of the easiest and most affordable ways to whiten your teeth at home is to use whitening toothpaste or kits. "Whitening strips use peroxide-based gels to lift surface stains, but they may contain other ingredients and preservatives, which may increase sensitivity," Rajpal said, adding that "LED kits often enhance this process with light to accelerate results."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Illinois becomes 1st state to require student mental health screenings
Illinois becomes 1st state to require student mental health screenings

Yahoo

time23 minutes ago

  • Yahoo

Illinois becomes 1st state to require student mental health screenings

For students in Illinois, mental health screenings will soon be required alongside annual vision and hearing exams. Illinois Gov. JB Pritzker signed a bill into law Thursday that will require public school students in grades 3 through 12 in the state to undergo a mental health screening each year. The change will go into effect in the 2027-2028 school year with at least one screening per student required annually, according to a press release from Pritzker's office. Pritzker also said the new legislation makes Illinois the first state to mandate universal mental health assessments for public school students. "At a time when our kids are struggling with anxiety and depression more than ever before, it's our responsibility to ensure that young people have all the support that they need to get the help that they deserve," Pritzker said in remarks at the signing ceremony. "Our goal is an integrated, comprehensive approach to quality mental and behavioral health services for young people across the state," Pritzker added, saying the legislation will pave the way for schools to receive resources and support to implement the new push for screenings. Kids who own smartphones before age 13 have worse mental health outcomes: Study The bill, SB1560, encourages schools to connect student caregivers and parents with the Behavioral Health Care and Ongoing Navigation or BEACON Portal, a tool launched in January that can provide information about available mental health resources and services. Illinois' move comes two months after the Trump administration pulled funding for about $1 billion in mental health grants. The Department of Education said in May that the grants would be discontinued because the money was going to "race-based actions" instead of mental health services in schools. Trump administration discontinues $1 billion in school mental health grants Students' mental health has been top of mind ahead of the back-to-school season. According to the Centers for Disease Control and Prevention, anxiety and depression are some of the most common mental health conditions diagnosed in children between the ages of 3 and 17, with mental health being a significant concern among teens. The Illinois State Board of Education has until Sept. 1, 2026, to provide schools with guidance and policies to implement the mandated mental health screenings. The state is also promising schools free screening tools and access to technology to fulfill the mandate. Solve the daily Crossword

Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Yahoo

time23 minutes ago

  • Yahoo

Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause of vision loss in people over the age of 60 With two refills per year, Susvimo maintained vision and stabilised the retina for five years, with durability maintained in approximately 95% of patients Susvimo was well tolerated over five years and has a well-characterised safety profile Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.1 Results show that Susvimo's immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States. 'These long-term results reinforce Susvimo's ability to maintain vision and retinal drying over a long period of time for people with nAMD, the leading cause of vision loss in people over age 60,' said Levi Garraway, MD, PhD, Roche's chief medical officer and head of Global Product Development. 'These robust data reinforce our confidence in Susvimo's unique therapeutic approach, providing an effective alternative to regular eye injections while preserving vision in a sustained manner.' 'People with nAMD often experience suboptimal outcomes with real-world anti-VEGF treatment, largely due to the frequency of injections,' said study investigator John Kitchens, M.D., Retina Associates of Kentucky, who presented the data at ASRS. 'Continuous delivery of treatment with Susvimo may preserve vision in patients with nAMD for longer in real-world clinical use than IVT injections.' In the Portal study (n = 352), people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort; n = 220), while those originally treated with monthly intravitreal (IVT) ranibizumab injections in Archway received Susvimo and then refills every six months (IVT-Susvimo cohort; n = 132). Five-year results showed consistent and sustained disease control and retinal drying in a population who entered Archway with vision at or near peak levels after receiving an average of five intravitreal injections per standard of care. In the Susvimo cohort, best-corrected visual acuity (BCVA) was 74.4 letters at baseline and 67.6 letters at 5 years. In the IVT-Susvimo cohort, BCVA was 76.3 letters at baseline and 68.6 at 5 years. Half of all patients had better than 20/40 vision at five years (Snellen visual acuity test). Average central subfield thickness (CST) remained stable, with a 1.0 (95% CI: -13.1, 11.1) µm reduction from baseline in the Susvimo cohort, and a 10.3 (95% CI: -25.7, 5.0) µm reduction in the IVT-Susvimo cohort. The cohort of people who entered the Portal study from Archway is the largest cohort of people with nAMD to be followed prospectively and continuously for five years in a clinical study.1 Susvimo provides continuous delivery of a customised formulation of ranibizumab via the Port Delivery Platform, while other currently approved treatments may require eye injections as often as once per month. The Port Delivery Platform is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure, which introduces medicine directly into the eye, addressing certain retinal conditions that can cause vision loss. About the Archway study and its open-label extension study (Portal)1,2Archway (NCT03677934) was a randomised, multicentre, open-label phase III study evaluating the efficacy and safety of Susvimo refilled every six months at fixed intervals, compared to monthly IVT ranibizumab 0.5 mg in 415 people living with nAMD. Patients were randomized 3:2 to Susvimo (n = 248) or IVT ranibizumab injections (n = 167). Patients enrolled in Archway were responders to prior treatment with anti-VEGF therapy. In both study arms, patients were treated with at least three anti-VEGF injections within the six months prior to their Archway screening visit, with an average of five anti-VEGF injections before randomization. The primary endpoint of the study was the change in BCVA score from baseline at the average of Week 36 and Week 40. Secondary endpoints include safety, overall change in vision (BCVA) from baseline and change from baseline in centre point thickness over time. Patients who completed the study at week 96 were eligible to enter the Portal open-label extension study. In Portal, people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort), while those originally treated with monthly intravitreal (IVT) ranibizumab injections in Archway received the Susvimo implant and then refills every six months (IVT-Susvimo cohort). Portal is ongoing. About neovascular age-related macular degenerationAge-related macular degeneration (AMD) is a condition that affects the part of the eye that provides sharp, central vision needed for activities like reading.3 Neovascular or 'wet' AMD (nAMD) is an advanced form of the disease that can cause rapid and severe vision loss if left untreated.4,5 It develops when new and abnormal blood vessels grow uncontrolled under the macula, causing swelling, bleeding and/or fibrosis.5 Worldwide, around 20 million people are living with nAMD – the leading cause of vision loss in people over the age of 60 – and the condition will affect even more people around the world as the global population ages.3,6,7 About Susvimo® (Port Delivery System with ranibizumab)Approved in the United States by the Food and Drug Administration (FDA) for nAMD, diabetic macular edema (DME) and diabetic retinopathy (DR), Susvimo is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure.8,9 Susvimo continuously delivers a customised formulation of ranibizumab over time.8,9 Ranibizumab is a VEGF inhibitor designed to bind to and inhibit VEGF-A, a protein that has been shown to play a critical role in the formation of new blood vessels and the leakiness of the vessels.8-10The customised formulation of ranibizumab delivered by Susvimo is different from the ranibizumab IVT injection, a medicine marketed as Lucentis® (ranibizumab injection)*, which is approved to treat nAMD and other retinal diseases.11 About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by law. *Lucentis® (ranibizumab injection) was developed by Genentech, a member of the Roche Group. Genentech retains commercial rights in the United States and Novartis has exclusive commercial rights for the rest of the world. References[1] Kitchens J, et al. Five Year Outcomes in nAMD Patients Enrolled in the Archway Study and Treated With the PDS. Presented at: The American Society of Retina Specialists (ASRS) 2025 Annual Meeting; 2025 August 01; Long Beach, California, United States.[2] Regillo C, et al. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023;130(7):735-747.[3] Bright Focus Foundation. Age-related macular degeneration (AMD): facts & figures. [Internet; cited July 2025]. Available from: [4] Pennington KL, et al. Epidemiology of AMD: associations with cardiovascular disease phenotypes and lipid factors. Eye and Vision. 2016;3:34.[5] Little K, et al. Myofibroblasts in macular fibrosis secondary to nAMD - the potential sources and molecular cues for their recruitment and activation. EBioMedicine. 2018;38:283-91.[6] Connolly E, et al. Prevalence of AMD associated genetic risk factors and four-year progression data in the Irish population. British Journal of Ophthalmology. 2018 Feb;102:1691-95.[7] Wong WL, et al. Global prevalence of AMD and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health. 2014 Feb;2:106-16.[8] US Food and Drug Administration (FDA). Highlights of prescribing information, Susvimo. 2021. [Internet; cited July 2025]. Available from: [9] Holekamp N, et al. Archway randomised phase III trial of the PDS with ranibizumab for neovascular age-related macular degeneration (nAMD). Ophthalmology. 2021.[10] Heier JS, et al. The angiopoietin/tie pathway in retinal vascular diseases: A review. The Journal of Retinal and Vitreous Diseases. 2021;41:1-19.[11] US FDA. Highlights of prescribing information, Lucentis. 2012. [Internet; cited April 2025]. Available from: [12] US FDA. Highlights of prescribing information, Vabysmo. 2024. [Internet; cited April 2025]. Available from: [13] European Medicines Agency. Summary of product characteristics, Vabysmo. [Internet; cited April 2025]. Available from: Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: Hans Trees, PhDPhone: +41 79 407 72 58 Sileia UrechPhone: +41 79 935 81 48 Nathalie AltermattPhone: +41 79 771 05 25 Lorena CorfasPhone: +41 79 568 24 95 Simon GoldsboroughPhone: +44 797 32 72 915 Karsten KleinePhone: +41 79 461 86 83 Kirti PandeyPhone: +49 172 6367262 Yvette PetillonPhone: +41 79 961 92 50 Dr Rebekka SchnellPhone: +41 79 205 27 03 Roche Investor Relations Dr Bruno EschliPhone: +41 61 68-75284e-mail: Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: Dr Birgit MasjostPhone: +41 61 68-84814e-mail: Investor Relations North America Loren KalmPhone: +1 650 225 3217e-mail: Attachment Media Investor Release Susvimo Archway study english

Restaurant Workers, Tell Us The Filthy Secrets Hiding Behind The Kitchen Doors
Restaurant Workers, Tell Us The Filthy Secrets Hiding Behind The Kitchen Doors

Yahoo

time23 minutes ago

  • Yahoo

Restaurant Workers, Tell Us The Filthy Secrets Hiding Behind The Kitchen Doors

If you've ever worked or currently work in food service, you know verrrrrry well that things aren't always so squeaky clean behind the scenes. From grease traps to food overloaded with salt and butter, to dishwashers who never wash their hands, sometimes it makes you never want to eat at a restaurant ever again. So if you're a current or former restaurant worker, we want to hear from you: What hygiene practices, whether in the kitchen, on the floor, or among staff and customers, are most often overlooked on the job? Perhaps you were a line cook and constantly saw roaches scurrying around the kitchen. When you said something to the restaurant owners, they said, verbatim, "All restaurants have roaches. Get used to it, bud." Related: Maybe you routinely saw dishwashers and wait staff using dirty, grease-covered rags, used to polish "clean" glasses. Even worse, the glasses were hardly even cleaned beforehand, sitting in cold, dirty water for hours at a time. Related: Or maybe you worked at a popular fast-food spot and once cleaned behind the ice cream and soda machines, only to discover it must have never been done before. What you found back there? A wall that appeared to be growing its own ecosystem, completely coated in black and green mold. Whatever it was, tell us — what's the most overlooked (or flat-out disgusting) hygiene practice you saw while working in food service? Let us know in the comments or at this anonymous form. Also in Community: Also in Community: Also in Community: Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store